Heart Disease & Cardiology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

This Phase 3 trial is studying maridebart cafraglutide, a drug aimed at reducing serious heart problems like heart attacks and strokes in adults who have atherosclerotic cardiovascular disease and are overweight or obese. If successful, it could provide an important new treatment option alongside existing care for people managing these conditions. The study is recruiting participants worldwide and its results may soon influence how heart disease is treated in patients with excess weight.

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

This Phase 3 trial is testing olpasiran, a medication designed to lower lipoprotein(a), a substance linked to increased heart disease risk. The study focuses on preventing first major cardiovascular events such as heart attacks in people with high lipoprotein(a) levels. Recruiting across several countries, this research could lead to new ways to protect at-risk individuals from serious heart problems.

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

This large Phase 3 trial is evaluating retatrutide, a once-weekly treatment, in adults who have obesity along with heart or kidney disease. The goal is to see if retatrutide can reduce the chance of major heart attacks, strokes, and kidney failure. While not currently recruiting, the study involves thousands of participants worldwide and aims to provide evidence on managing both heart and kidney health in people with obesity.

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

This completed Phase 3 trial tested Rexlemestrocel-L, a cell therapy, in adults with chronic heart failure caused by left ventricular systolic dysfunction. The treatment aimed to improve heart function and reduce hospital visits related to heart failure. Conducted across many sites in the US and Canada, the results from this study may offer new hope for patients living with chronic heart failure.

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

This Phase 3 trial evaluated milvexian, an oral medication, in people who recently experienced an acute coronary syndrome event such as a heart attack. With over 14,000 participants enrolled worldwide, the study aimed to find out if milvexian can lower the risk of future serious heart problems. Results from this trial are expected to help shape future treatment options for patients recovering from acute coronary events.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.